4.7 Article

Clinical Impact and Cost-effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa: Test Timing and Frequency

Journal

JOURNAL OF INFECTIOUS DISEASES
Volume 214, Issue 9, Pages 1319-1328

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiw379

Keywords

human immunodeficiency virus; early infant HIV diagnosis; birth testing; nucleic acid test; cost-effectiveness

Funding

  1. World Health Organization
  2. National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [R01 HD079214]
  3. National Institute of Allergy and Infectious Diseases (NIAID) [K01 AI078754, R01 AI058736, R37 AI093269]
  4. International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) group
  5. Massachusetts General Hospital Executive Committee on Research

Ask authors/readers for more resources

Background. Diagnosis of human immunodeficiency virus (HIV) infection during early infancy (commonly known as early infant HIV diagnosis [EID]) followed by prompt initiation of antiretroviral therapy dramatically reduces mortality. EID testing is recommended at 6 weeks of age, but many infant infections are missed. Design/Methods.aEuro integral We simulated 4 EID testing strategies for HIV-exposed infants in South Africa: no EID (diagnosis only after illness; hereafter, no EID), testing once (at birth alone or at 6 weeks of age alone; hereafter, birth alone and 6 weeks alone, respectively), and testing twice (at birth and 6 weeks of age; hereafter birth and 6 weeks). We calculated incremental cost-effectiveness ratios (ICERs), using discounted costs and life expectancies for all HIV-exposed (infected and uninfected) infants. Results.aEuro integral In the base case (guideline-concordant care), the no EID strategy produced a life expectancy of 21.1 years (in the HIV-infected group) and 61.1 years (in the HIV-exposed group); lifetime cost averaged $1430/HIV-exposed infant. The birth and 6 weeks strategy maximized life expectancy (26.5 years in the HIV-infected group and 61.4 years in the HIV-exposed group), costing $1840/infant tested. The ICER of the 6 weeks alone strategy versus the no EID strategy was $1250/year of life saved (19% of South Africa's per capita gross domestic product); the ICER for the birth and 6 weeks strategy versus the 6 weeks alone strategy was $2900/year of life saved (45% of South Africa's per capita gross domestic product). Increasing the proportion of caregivers who receive test results and the linkage of HIV-positive infants to antiretroviral therapy with the 6 weeks alone strategy improved survival more than adding a second test. Conclusions.aEuro integral EID at birth and 6 weeks improves outcomes and is cost-effective, compared with EID at 6 weeks alone. If scale-up costs are comparable, programs should add birth testing after strengthening 6-week testing programs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available